Department of Cardiology, Carmel Medical Center, Haifa, Israel.
Department of Cardiology, Carmel Medical Center, Haifa, Israel.
Heart Lung Circ. 2022 Jul;31(7):1023-1028. doi: 10.1016/j.hlc.2022.01.013. Epub 2022 Mar 8.
Transfemoral transcatheter aortic valve replacement (TAVR) procedures require secondary vascular access for inserting accessory catheters and performing percutaneous repair of femoral artery injury. Use of the transbrachial approach for secondary vascular access in TAVR procedures has not been reported.
This study identified 48 patients at the current institution who had undergone transfemoral TAVR utilising transbrachial secondary vascular access. Efficacy and safety of this strategy for achieving a successful totally percutaneous procedure were examined. Study endpoints were occurrence of vascular complications and bleeding related to transbrachial access, as well as periprocedural and 1-year mortality.
Mean patient age was 80±7 years and Society of Thoracic Surgeons Predicted Risk of Mortality score was 10.6±3.1. Sizes of sheaths inserted into the brachial artery were 6 Fr (85%), 8 Fr (2%), and 9 Fr (13%). Transbrachial access was used for delivering stent grafts to the femoral artery in 13% of the patients, inflation of an occlusive balloon within the iliac artery in 10%, and treatment of iatrogenic femoral artery stenosis in 2%. Successful valve replacement was achieved in all cases. Brachial sheaths were removed by manual compression following administration of protamine sulfate. There were no major access site complications or VARC-3 type ≥2 bleeding related to the brachial vascular access. Brachial artery occlusion occurred in two patients (4%) who underwent surgical vascular repair. Two (2) additional patients developed mild arm ischaemia, which was treated conservatively. Periprocedural mortality was 0% and early mortality was 8%.
Transbrachial secondary access in TAVR procedures was feasible and enabled percutaneous vascular repair in cases of femoral artery injury.
经股动脉经导管主动脉瓣置换术(TAVR)需要二次血管通路来插入辅助导管并进行股动脉损伤的经皮修复。在 TAVR 手术中,经肱动脉入路用于二次血管通路尚未有报道。
本研究确定了当前机构中 48 例接受经股 TAVR 治疗的患者,他们采用经肱动脉的二次血管通路。检查了这种策略实现完全经皮手术成功的疗效和安全性。研究终点是与经肱动脉入路相关的血管并发症和出血的发生,以及围手术期和 1 年死亡率。
患者平均年龄为 80±7 岁,胸外科医师协会预测死亡率评分(STS Predicted Risk of Mortality score)为 10.6±3.1。肱动脉插入的鞘管尺寸为 6Fr(85%)、8Fr(2%)和 9Fr(13%)。13%的患者使用经肱动脉入路将支架移植物输送至股动脉,10%的患者使用髂动脉内闭塞球囊充气,2%的患者治疗医源性股动脉狭窄。所有病例均成功进行了瓣膜置换。在给予硫酸鱼精蛋白后,通过手动压迫取出肱动脉鞘管。无主要入路部位并发症或与肱动脉血管通路相关的 VARC-3 型≥2 级出血。2 例(4%)患者发生肱动脉闭塞,行手术血管修复。另外 2 例(2%)患者发生轻度手臂缺血,经保守治疗。围手术期死亡率为 0%,早期死亡率为 8%。
TAVR 手术中经肱动脉的二次入路是可行的,能够在股动脉损伤时进行经皮血管修复。